Experience

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common…

Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…

Davis Polk is advising Affymetrix, Inc. in connection with its sale to Thermo Fisher Scientific Inc. for a total equity value of approximately $1.3 billion. The transaction, which is…

Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…

Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock…

Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies, Inc. Aimmune Therapeutics sold 11,499,999 shares of its…

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000 shares of common stock of Natera, Inc. Natera’s common…

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…

Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…